Atorvastatin Calcium Research Articles

Stability Indicating RP-HPLC-DAD Method For Simultaneous Estimation of Atorvastatin Calcium and Teneligliptin Hydrobromide Hydrate in Synthetic Mixture

RP-HPLC stability indicating specific, precise, accurate, cost-effective and isocratic method was developed and validated for quantitative analysis of Atorvastatin calcium and Teneligliptin hydrobromide hydrate in synthetic mixture with presence of its degradants. Separation was achieved by using Gemini, C18, using mobile phase composition [Methanol: 20 mM Ammonium acetate (70:30 v/v)] using a flow rate of 1.0 ml/min, injection volume 10µl with UV detection at 245 nm. Atorvastatin calcium and Teneligliptin hydrobromide hydrate were eluted with retention time 7.47min and 4.74min respectively. This method was validated as per ICH guideline Q2(R1). The calibration plots were over the concentration range of 10-100 μg/ml and 5-50 μg/ml for Atorvastatin calcium and Teneligliptin hydrobromide hydrate with correlation coefficient 1 and 0.9999 respectively. Percentage recovery was obtained between 98.00-100.51 % and 98.90-100.7 % for Atorvastatin calcium and Teneligliptin hydrobromide hydrate respectively. In case of Precision, Repeatability and Robustness RSD should be found less than 2. LOD were found to be 1.22 μg/ml and 0.54 μg/ml and LOQ were found to be 3.70 μg/ml and 1.64 μg/ml for Atorvastatin calcium and Teneligliptin hydrobromide hydrate respectively. The results showed that the developed method is appropriate for the routine analysis of Atorvastatin calcium and Teneligliptin hydrobromide hydrate in a synthetic mixture in presence of its degradants.

Development of the spectrophotometric method for the determination of atorvastatin in tablets by using bromothymol blue

The aim of the work was to develop a simple, economic, fast, reliable, and eco-friendly spectrophotometric method for the determination of atorvastatin in tablets based on the reaction with bromothymol blue (BTB).
 Material and methods. A double–beam Shimadzu UV-Visible spectrophotometer, with spectral bandwidth of 1 nm wavelength accuracy ±0.5 nm, Model –UV 1800 (Japan), Software UV-Probe 2.62 was used to measure absorbance of the resulting solution. Pharmacopeial standard sample of atorvastatin calcium and BTB were provided by Sigma-Aldrich (≥98 %, HPLC). The used dosage forms of atorvastatin: tablets Atorvastatin 10 mg and 20 mg.
 Results and discussion. The method of spectrophotometric determination of the quantitative content of atorvastatin calcium based on its reaction with BTB in ethyl acetate medium has been developed. The stoichiometric ratios of the reactive components as 1:1 were obtained by the methods of continuous changes and the saturation method. Linearity regression equation was y=0.0017x+0.0496 and the obtained correlation coefficient was R2=0.9993. The linear relationship was found between absorbance at λmax and concentration of medicine in the range 15.48–154.80 µg/mL. The LOD and LOQ values were calculated to be 4.85 µg/mL and 14.71 µg/mL respectively. Spectrophotometric method for the determination of atorvastatin in tablets using BTB was developed in accordance with GAC principles.
 Conclusions. A simple, economic, fast, reliable and eco-friendly spectrophotometric method was developed for the determination of atorvastatin calcium in tablets based on the reaction with BTB and validated according to the standardized validation procedure by the standard method. It was proved that according to such validation characteristics as linearity, precision, accuracy, and robustness the proposed method met the requirements of SPhU

Response Surface Method for the Simultaneous Estimation of Atorvastatin and Olmesartan

The simultaneous estimation of Atorvastatin Calcium (ATS) and Olmesartan Medoxomil (OLM) in bulk and pharmaceutical dosage forms, a new, quick, and cost-effective Reverse Phase High Performance Liquid Chromatography (RP-HPLC) method has been developed. The experimental design was used to achieve multivariate optimization of the RP-HPLC experimental conditions. Three independent variables were used to create mathematical models: Acetonitrile content in the mobile phase composition, buffer pH, and flow rate. Here, the applied model was central composite design (CCD) to research the response surface methodology and study the effects of independent factors. The Shimadzu (LC 20 AT VP) HPLC system with Spinchrom software has been used. Zodiac, C18 (250×4.6 ID) 5μm column, phosphate buffers, and acetonitrile were used as mobile phase in the ratio 40:60 v/v with a flow rate 1.15 mL/min. The eluent was monitored at 212 nm using the Prominence UV-Visible detector. The retention time for OLM and ATS was 2.673 and 3.717, respectively. The optimized procedure was validated as per ICH guidelines. The correlation coefficient of OLM and ATS was 0.9869 and 0.9832. The % of recovery was 98.59, 99.68 %. OLM had a LOD of 17.568 μg/mL, while ATS had a LOD of 12.88 μg/mL. OLM had a LOQ of 53.24 μg/mL, while ATS had a LOQ of 39.04 μg/mL. The pH aqueous phase, solvent composition, and flow rate were the most stringent variables affecting the responses, according to the 3D response surface graphs. A new accurate and precise RP-HPLC approach has been developed and validated and used to regularly analyse OLM and ATS.
 HIGHLIGHTS
 
 A new, quick, and cost-effective RP-HPLC method for the simultaneous estimation of Atorvastatin Calcium and Olmesartan Medoxomil in bulk and pharmaceutical dosage forms
 RP-HPLC method developed by experimental design and response surface method
 Developed method was validated as per ICH guidelines
 
 GRAPHICAL ABSTRACT

Effect of Enalapril Combined with Bisoprolol on Cardiac Function and Inflammatory Indexes in Patients with Acute Myocardial Infarction.

Objective The use of enalapril in combination with bisoprolol in patients with acute myocardial infarction (AMI) was studied for its effect on cardiac function and inflammatory parameters. Methods Sixty-two cases of AMI patients admitted to our clinic from November 2019 to November 2021 were selected for the study and grouped according to the random number table method, those enrolled were given conventional treatment such as oxygenation, absolute bed rest, and sedation, and administered low molecular heparin, aspirin, atorvastatin calcium tablets, clopidogrel, and nitrates. The control group (31 cases) was treated with enalapril maleate folic acid tablets, and the treatment group (31 cases) was treated with bisoprolol fumarate tablets on top of the control group, and the efficacy, adverse effects, cardiac function, inflammatory indexes, and oxidative stress indexes of the two arms were contrasted. Results The incidence of adverse reactions in the therapy cohort was 12.90% higher than that in the controlled arm, but the discrepancy was not medically relevant (P < 0.05). The SOD level was larger than the concentration in the corresponding drug therapy group, and the MDA level was lower than the concentration in the respective test cases (P < 0.05); the incidence of 12.90% adverse reactions in the treatment period was lower than that of 16.13% in the specific drug therapy group, but the variance was not scientifically evident (P > 0.05). Conclusion Enalapril application combined with bisoprolol in AMI patients is beneficial to boost the efficacy, promote the improvement of cardiac function, reduce the inflammatory response, and improve the oxidative stress with fewer adverse effects, which can ensure the therapeutic security.

Efficacy of Clopidogrel Combined with Atorvastatin Calcium in the Treatment of Cerebral Infarction and Analysis of Its Influence on TC, TG and LDL-C Indexes

Efficacy of Clopidogrel Combined with Atorvastatin Calcium in the Treatment of Cerebral Infarction and Analysis of Its Influence on TC, TG and LDL-C Indexes

Related Factors of Cerebral Hemorrhage after Cerebral Infarction and the Effect of Atorvastatin Combined with Intensive Nursing Care.

Background Cerebral infarction is a common neurological disease with high incidence, which is the main factor causing death and disability in adults in China. Cerebral hemorrhage transformation is a common clinical complication. High NIHSS score at admission, atrial fibrillation, and small artery occlusion cerebral infarction can increase the risk of cerebral infarction complicated with hemorrhage transformation. Aim To explore the related factors of cerebral hemorrhage transformation after cerebral infarction and the value of atorvastatin calcium tablets combined with early intensive care measures. Methods In this study, a case-control study was conducted. Sixty patients with hemorrhagic transformation after cerebral infarction admitted to the Department of Neurology of our hospital from January 2017 to June 2021 were selected as the observation group, and 90 patients with cerebral infarction without hemorrhagic transformation during the same period were selected as the control group. The risk factors of hemorrhagic transformation after cerebral infarction were analyzed. Results The results of logistic regression model showed that the increased National Institutes of Health Stroke Scale (NIHSS) score at admission, hypertension, atrial fibrillation, TOAST classification of small artery occlusion, and large infarction lesions were the risk factors for hemorrhagic transformation in patients with cerebral infarction (P < 0.05). After 2 weeks and 4 weeks of treatment, the NIHSS scores of the intervention group were lower than those of the conventional group (P < 0.05). NIHSS scores of the two groups after treatment were significantly lower than those before treatment (P < 0.05). After three months of treatment, the patients in the intervention group with GOS score of 5 points accounted for 16.67%, and the patients with GOS score of 4 points accounted for 56.67%. The patients in the conventional group with GOS score of 5 points accounted for 6.67%, and the patients with GOS score of 4 points accounted for 33.33%. The prognosis of the intervention group was better than that of the conventional group on the whole (P < 0.05). Conclusion Patients with hypertension, large infarction lesions, high NIHSS score at admission, atrial fibrillation, and small artery occlusion cerebral infarction can increase the risk of bleeding transformation in patients with cerebral infarction. For patients with bleeding transformation, atorvastatin calcium tablets combined with early intensive nursing intervention has a certain value for improving the prognosis of patients.

Osteonecrosis of the jaw in patients taking Atorvastatin: Case series

Osteonecrosis of the jawbones commonly seen in patients taking bisphosphonates, denosumab, and several antiangiogenic medications with several oral factors such as tooth extraction or dental infection. Currently, patients taking Simvastatin, a medication commonly used to treat hypercholesteremia, were reported of developing osteonecrosis of the jaw. Thus, it is important that clinicians know about the risk of osteonecrosis for patients taking this hypercholesteremia medication. It is not known if the undesirable effect only occurs with Simvastatin or other types of statin medication. We report in detail three cases of osteonecrosis of patients taking Atorvastatin calcium, a second-generation statin medication.

Fabrication of a shell-core fixed-dose combination tablet using fused deposition modeling 3D printing

Fixed-dose combinations (FDCs) achieve optimal goals for treatment with minimal side effects, decreased administration of large number of tablets, thus, greater convenience, and improved patient compliance. However, conventional FDCs do not have a guaranteed place in the future of patient-centered drug development because of the difficulty in achieving dose titration of each drug for individualized specific health needs and desired therapeutic outcomes. In the current study, FDCs of two antihypertensive drugs were fabricated with two distinct compartments using fused deposition modeling three-dimensional printing (FDM-3DP). Atorvastatin calcium and Amlodipine besylate loaded filaments were prepared by hot-melt extrusion. Shell-core FDC tablets were designed to have different infills for individualized dosing. Differential scanning calorimetry and powder X-ray diffraction revealed that both drugs were transformed into amorphous forms within the polymeric carriers. The fabricated tablets met the United States Pharmacopeia acceptance criteria for friability, content uniformity, and dissolution testing. The fabricated tablets were stable at room temperature with respect to drug content and thermal behavior over six months. This dynamic dosage form provides flexibility in dose titration and maintains the advantages of FDCs, thus achieving optimal therapeutic outcomes in different healthcare facilities.

Clinical Study on Aspirin and Atorvastatin Calcium in the Treatment of Hypertension Combined with Carotid Atherosclerosis

Clinical Study on Aspirin and Atorvastatin Calcium in the Treatment of Hypertension Combined with Carotid Atherosclerosis

. Preparation and Characterization of Atorvastatin Calcium Trihydrate-cyclodextrin Inclusion Complex

Atorvastatin calcium (ATR) is an antihyperlipidemic agent used for lowering blood cholesterol levels. However, it is very slightly soluble in water with poor oral bioavailability, which interferes with its therapeutic action. It is classified as a class II drug according to Biopharmaceutical Classification System (low solubility and high permeability).

Analysis of the Efficacy of Clopidogrel and Atorvastatin Calcium in Treating Hypertension Combined with Carotid Atherosclerosis

Analysis of the Efficacy of Clopidogrel and Atorvastatin Calcium in Treating Hypertension Combined with Carotid Atherosclerosis

Acupuncture Combined with Traditional Chinese Medicine and Drug Therapy for the Treatment of Cerebral Infarction (Phlegm-Blood Stasis Syndrome) and Carotid Atherosclerotic Plaque: A Preliminary Randomized Controlled Study.

Carotid atherosclerotic plaque (CAP) is one of the leading causes of cerebral infarction. Western medicine usually uses lipid-lowering drugs to stabilize plaques. Currently, studies reporting on drugs that can reduce plaques are lacking. Here, we performed a randomized controlled study to investigate the effectiveness of acupuncture combined with drug therapy (TCM and Western) to treat cerebral infarction (phlegm-blood stasis syndrome) and CAP. The control group was treated with atorvastatin calcium tablets (20 mg/d, po for 15 days). The treatment group received atorvastatin calcium tablets 20 mg, traditional Chinese medicine (TCM) decoctions (two matured substance decoction plus peach kernel and Carthamus four substance decoction plus Chinese hawthorn fruit 20 g, gold theragran 20 g, and red yeast rice 3 g), and acupuncture therapy, once daily for 15 days as one treatment course. The patients' neurological deficit score, ultrasonic testing of the carotid artery, and lipoprotein-associated phospholipase A2 (Lp-PLA2) were evaluated. Our findings showed no significant difference in the evaluated indices between the two groups before treatment (P > 0.05). However, compared with the control group after 15 days of treatment and within each group before and after treatment, the differences were significant (P < 0.05). In conclusion, acupuncture combined with drug therapy demonstrated promising effectiveness in treating cerebral infarction (phlegm-blood stasis syndrome) and CAP.

Study on the Application of Metoprolol Combined with Atorvastatin Calcium in the Treatment of Angina Pectoris of Coronary Heart Disease

Study on the Application of Metoprolol Combined with Atorvastatin Calcium in the Treatment of Angina Pectoris of Coronary Heart Disease

Analytical quality by design assisted RP-HPLC method for quantifying atorvastatin with green analytical chemistry perspective

Analytical Quality by design and greener solvent methods were applied to optimize the High-Performance Liquid Chromatographic method for assessing atorvastatin calcium in bulk and pharmaceutical dosage forms are highlighted in the present work. The research used a rotatable central composite design, with the volume of ethanol and flow rate chosen as critical method variables for examining their impact on critical analytical attributes such as tailing factor, capacity factor, and theoretical plates. On a Zorbax Eclipse plus C18 column (150 × 4.6 mm, 5 µm), optimal chromatographic separation was achieved using 0.5% v/v aqueous acetic acid: ethanol (42.5: 57.5 v/v) flowing at 0.91 mL/min. Photodiode array detection was made at 246 nm. The retention time was 6.27 min for atorvastatin and the run time was 12 min. The linearity of the proposed method was perceived in the range of 10 to 150 µg/mL. The outcomes of other validation studies were likewise satisfactory. The suggested HPLC method was assessed concerning its greenness and ecological nature by the Green Analytical Procedure Index; Analytical Method Greenness Score; and analytical Eco-Scale score approach along with software-based evaluation AGREE metrics, which affirmed the excellent greenness and safety of the present work. This AQbD and greener technology were proven adequate for regular analysis of atorvastatin calcium in the pharmaceutical tablet dose without damaging the environment.

Guanxinping Tablets Inhibit ET-1-Induced Proliferation and Migration of MOVAS by Suppressing Activated PI3K/Akt/NF-κB Signaling Cascade

Background/Aim Abnormal proliferation and migration of vascular smooth muscle cells is one of the main causes of atherosclerosis (AS). Therefore, the suppression of abnormal proliferation and migration of smooth muscle cells are the important means for the prevention and inhibition of AS. The clinical effects of Guanxinping (GXP) tablets and preliminary clinical research on the topic have proved that GXP can effectively treat coronary heart disease, but its underlying mechanism remains unclear. This study aimed to confirm the inhibitory effect of GXP on the abnormal proliferation of mouse aortic vascular smooth muscle (MOVAS) cells and to explore the underlying mechanism. Methods MOVAS cells were divided into two major groups: physiological and pathological groups. In the physiological group, MOVAS cells were directly stimulated with GXP, whereas in the pathological group, the cells were stimulated by endothelin-1 (ET-1) before intervention by GXP. At the same time, atorvastatin calcium, which effectively inhibits the abnormal proliferation of MOVAS cells, was used in the negative control group. CCK8 assay, scratch test, ELISA, Western blotting, and immunofluorescence staining were performed to observe the proliferation and migration of MOVAS cells and the expression levels of related factors after drug intervention in each group. Results In the physiological group, GXP had no significant effect on the proliferation and migration of MOVAS cells and the related factors. In the pathological group, a high dose of GXP reduced the abnormal proliferation and migration of MOVAS cells. Further, it reduced the expression levels of PI3K; inhibited the phosphorylation of Akt (protein kinase B); upregulated IκB-α levels; prevented nuclear factor kappa B (NF-κB) from entering the nucleus; downregulated the expression of interleukin 6 (IL6), IL-1β, and iNOS; and upregulated the ratio of apoptosis-related factor Bax/Bcl-2. There was no significant difference between the high-dose GXP group and the atorvastatin calcium group (negative control group). Conclusion Our findings revealed that GXP was able to inhibit the proliferation and migration of MOVAS cells by regulating the PI3K/Akt/NF-κB pathway.

Development of Atorvastatin Calcium Biloaded Capsules for Oral Administration of Hypercholesterolemia.

The goal of this study was to develop atorvastatin (ATN) calcium biloaded, i.e., immediate release (IR) and sustained release (SR) capsules that would promote the quick onset of action and a better dissolution profile on both the IR and SR aspects. The IR granules were prepared by the wet granulation method, and an aqueous solubility study proved that the IR granules released the ATN within 25 min compared to the pure drug due to the addition of PEG and super disintegrants such as croscarmellose (CC) and crospovidone (CP). The sustained release nanoparticles (SR-NPs) were synthesized using a solvent evaporation technique and an optimal combination of hydrophilic and hydrophobic polymers. The addition of a hydrophobic polymer to a hydrophilic polymer delays drug release, resulting in a sustained and controlled release lasting up to 12 hours. The drug release of ATN from SR nanoparticles followed the Higuchi and Korsmeyer–Peppas models and had first-order kinetics (r2 = ???). Fourier transform infrared spectrophotometry, powder X-ray diffraction, and differential scanning calorimetric analysis were used to test the prepared biloaded capsules, and the results showed that there was no significant interaction between the polymers, excipients, and drug. The SEM and DLS analysis clearly demonstrated that drug particles in a continuous layer were enclosed by polymers at the nanoscale. To summarise, integrating both layers into a single capsule resulted in a superior release profile and patient compliance. Finally, prepared biloaded capsules were discovered to exhibit both an IR and an SR profile.

The persistence and crystallization behavior of atorvastatin calcium amorphous dispersions in polyvinylpyrrolidone

The persistence of amorphous atorvastatin calcium has been studied as a function of the amorphization method, polymer content, and relative humidity during storage. For amorphization, ball milling, freeze drying, and spray drying have been used. Polyvinylpyrrolidone K40 (PVP) was mixed with atorvastatin in a wide range of concentrations and the resulting amorphous dispersions were subjected to storage conditions with different levels of relative humidity. The analysis of the glass transition temperature of the various samples demonstrates that interactions between atorvastatin calcium and PVP are unfavorable, leading to a destabilization of amorphous atorvastatin, which becomes therefore more prone to recrystallisation. However, mixtures made with spray drying in methanol show an increased glass transition temperature and an increased stability against recrystallisation. PVP may act as a humidity reservoir providing water molecules to amorphous atorvastatin calcium and thus promoting crystallization of the hydrate form. For atorvastatin calcium, the most persistent amorphous sample appears to be that without PVP. It possesses a glass transition temperature as high as 143 °C and it remains amorphous for at least a year independent of the humidity level it is subjected to.

Improvement of solubility and dissolution rate of Biopharmaceutical Class II drug atorvastatin calcium by using an essential amino acid L-leucine

Background and objective: Atorvastatin calcium is an antihyperlipidemic agent that is characterized by low aqueous solubility and high membrane permeability. This study was designed to enhance the solubility and the dissolution rate of atorvastatin calcium in the water and physiological pH (pH 6.8) by using L-Leucine as solubilizing agent utilizing different solid dispersion methods. Methods: Solid dispersion masses were prepared by kneading method and solvent evaporation methods at different weight ratios (1:1, 1:2: and 1:4) of the drug to the carrier. Saturated solubility studies were carried out in aqueous media, and the in-vitro studies were performed in physiological pH Fourier transform infrared spectroscopy were used to detect any interaction between the drug and the carrier. Results: The kneading method increase the solubility of atorvastatin calcium by 1.27, 1.43, and 1.81 folds from kneading method 1, kneading method 2, and kneading method 3, respectively. The solubility of atorvastatin calcium in solvent evaporation 1, solvent evaporation 2, and solvent evaporation 4 was increased by 2.53, 2.66, and 3.1 folds (P = 0.002). Solvent evaporation 2 (1:2 ratio) was selected as the best formula in terms of dissolution profile because it has faster and complete drug release after 5 minutes when compared with solvent evaporation 1, kneading method 1, kneading method 2, and kneading method 3 and contain less amount of L-Leucine when compared with solvent evaporation 3. Fourier transform infrared studies indicated no chemical reaction between the drug and carrier. Conclusion: L-leucine significantly improved the solubility and dissolution profile of poorly water-soluble atorvastatin calcium.

Preparation and Evaluation of Antihypercholesterolemic Activity of Atorvastatin Calcium-Maleic Acid Co-Amorphous Solids

Atorvastatin calcium is a statin drug used for antihypercholesterolemic. The oral bioavailability of atorvastatin calcium is relatively low because it is poorly soluble in water. The low oral bioavailability of the drug causes a decrease in its therapeutic effectiveness. This study aimed to increase the solubility of atorvastatin calcium through the formation of co-amorphous solids and evaluate its activity as antihypercholesterolemic. Atorvastatin calcium was prepared into co-amorphous solids with a maleic acid coformer using the spray drying method. Solids characterization was carried out using Powder X-Ray Diffraction (PXRD), Differential Scanning Calorimetry (DSC), Fourier Transforms Infra Red (FTIR), and Scanning Electronic Microscopy (SEM). The solubility test was carried out using the shaking method, while the evaluation of antihypercholesterolemic was carried out in vivo in experimental animals. The results of the analysis of diffractograms, thermograms, FTIR spectra, and micrograph images showed that the atorvastatin calcium-maleic acid solids prepared by spray drying were a co-amorphous solid. The atorvastatin calcium-maleic acid co-amorphous solids had a greater solubility in water (p&lt;0.05) when compared to pure atorvastatin calcium. However, the in vivo antihypercholesterolemic activity results in experimental animals showed that the cholesterol-lowering activity of the atorvastatin calcium-maleic acid co-amorphous solidswas not significantly different (p&gt;0.05) with pure atorvastatin calcium. This phenomenon is thought to be because atorvastatin calcium from co-amorphous solids in solution is more present as a charged fraction, affecting the permeability and absorption process.

Determination of arsenic, cadmium, mercury, lead and nickel as elemental impurities in atorvastatin calcium by inductively coupled mass spectrometer.

Atorvastatin calcium is employed as front-line treatment for cardiovascular diseases. According to the international conference on harmonization (ICH) guideline ICH Q3D, elemental impurities can come into drug products from various sources. These elemental impurities do not have any therapeutic benefit to the end-user. On the contrary, it harms the normal physiological system. Class 1 elements like arsenic, cadmium, mercury, and lead are inorganic impurities that can cause toxic effects on the human body. Nickel was used as a catalyst during the synthesis process of atorvastatin calcium. It comes under the Class-2A, can cause toxicity to humans, and must be quantified. A simple, fast, reliable inductively coupled plasma mass spectrometric method for the estimation of elemental impurities like arsenic, cadmium, mercury, lead, and nickel in atorvastatin calcium by open sample digestion technique was developed and validated in accordance with ICH Q3D and USP < 232 > and USP <233 > general chapter. Internal standards like indium, terbium, thallium, bismuth and yttrium were used to correct the non-spectral interferences that were generated during analysis. Gold was added to all solutions as it preserves mercury by amalgamation. The system performance was evaluated every time my performing system suitability parameters. The limits for all the elements were fixed in accordance with ICH Q3D. The limit of detection and the limit of quantification for all the five elements were estimated. Method specificity was proven by checking for interferences due to the sample matrix and other elements. Linearity of each element in standards was established from 25% to 200% of sample concentration, and correlation coefficients were found to be not less than 0.999. The accuracy of the method was demonstrated at three spiking levels at 50%, 100%, and 150% of the J-value for all the elements. The recoveries for all elements at each level were within the range of 90-120%. Method precision was proved at 100% J-value. The relative standard deviation of all elements was less than 5%. It concludes that this newly developed and validated reliable inductively coupled plasma mass spectrometric method for estimating of elemental impurities like arsenic, cadmium, mercury, lead, and nickel in atorvastatin calcium was within the permitted limit and suitable for routine use.